Stemade Biotech

stemade.com

Stemade Biotech Pvt. Ltd. Is the pioneer in the path-breaking concept of dental stem cells preservation in India, and is proud to be India’s first private dental stem cell bank. It provides an excellent opportunity for parents across India to safeguard their child’s health via flexible and affordable pricing plans. The collected dental stem cells can be potentially used to repair and cure 'tissue & organ related diseases' such as bone, cartilage, liver, diabetes, arthritis and many more. Stemade has pioneered this novel concept in India and Asia, having operations in more than 27 locations in India. Stemade aims to be present in at least 50 Indian cities within the first 2 quarters of this financial year. The company was established in year 2009 and launched commercial operations in November 2010. The company is spearheaded by Mr. Deepak Ghaisas, one of the pioneers of the IT revolution in India and has been Vice Chairman, Oracle Financial Services and CEO, iFlex India. Mr. Ghaisas is the first Indian CFO to win the prestigious CFO Asia Award.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

MEDICAL

CELLECTIS PRESENTS CLINICAL DATA ON AMELI-01 AND PRECLINICAL DATA ON MULTIPLEX ENGINEERING FOR SUPERIOR GENERATION OF CAR T-CELLS AT ASGCT 2023

Globenewswire | May 18, 2023

news image

Cellectis a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, today presents clinical data on its Phase 1 AMELI-01 clinical trial (evaluating UCART123) that were unveiled in an oral presentation at the 64th American Society of Hematology (ASH) annual meeting, as well as preclinical data on multiplex engineering for superior generation of CAR T-cells, at the American Society of Gene and Cell Therapy (ASGCT) 2023 A...

Read More

SARTORIUS STEDIM BIOTECH CLOSES ACQUISITION OF SLOVENIAN PURIFICATION SPECIALIST BIA SEPARATIONS

Sartorius | November 03, 2020

news image

Sartorius Stedim Biotech (SSB), a leading partner of the biopharma industry, successfully closed the acquisition of the Slovenian purification specialist BIA Separations. The transaction was completed on November 2, 2020, after receiving the required approvals. "BIA's portfolio is highly complementary to Sartorius Stedim Biotech. We are thus creating an excellent offering for the manufacturing of gene therapies and other advanced therapies, and are pleased to welcome 120 new employees,&...

Read More

MEDTECH

WITH "PRODRUGS FOR CANCER TREATMENT" PATENT, GATC HEALTH ENTERS ONCOLOGY MEDICINE MARKET

GATC Health Corp | April 22, 2022

news image

GATC Health, a biotech company that uses artificial intelligence and advanced multiomics to revolutionize drug discovery and disease prediction, announced that it filed a patent application for an innovative new prodrug designed to safely cross the blood-brain barrier (BBB) for cancer treatment. GATC Health's entry into the oncology drug discovery market is marked by this breakthrough, which was made possible by the company's innovative Multiomics Advanced TechnologyTM AI platform....

Read More

RESEARCH

CHEMISTRY42, AN AI SYSTEM FROM INSILICO, HAS BEEN INCORPORATED INTO UCB'S DRUG DISCOVERY PROGRAMMES

Insilico Medicine | March 15, 2021

news image

Insilico Medicine, an AI drug discovery company, reported that UCB will incorporate Insilico's Chemistry42™ into UCB's inward drug discovery pipeline. UCB's initial appropriation of Insilico Medicine's restrictive innovation will give UCB's researchers the capacity to plan novel hit compounds that fulfill various predefined boundaries quickly and smooth out lead enhancement. With the Chemistry42™ platform, UCB researchers will likewise lessen the endeavors and exp...

Read More
news image

MEDICAL

CELLECTIS PRESENTS CLINICAL DATA ON AMELI-01 AND PRECLINICAL DATA ON MULTIPLEX ENGINEERING FOR SUPERIOR GENERATION OF CAR T-CELLS AT ASGCT 2023

Globenewswire | May 18, 2023

Cellectis a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, today presents clinical data on its Phase 1 AMELI-01 clinical trial (evaluating UCART123) that were unveiled in an oral presentation at the 64th American Society of Hematology (ASH) annual meeting, as well as preclinical data on multiplex engineering for superior generation of CAR T-cells, at the American Society of Gene and Cell Therapy (ASGCT) 2023 A...

Read More
news image

SARTORIUS STEDIM BIOTECH CLOSES ACQUISITION OF SLOVENIAN PURIFICATION SPECIALIST BIA SEPARATIONS

Sartorius | November 03, 2020

Sartorius Stedim Biotech (SSB), a leading partner of the biopharma industry, successfully closed the acquisition of the Slovenian purification specialist BIA Separations. The transaction was completed on November 2, 2020, after receiving the required approvals. "BIA's portfolio is highly complementary to Sartorius Stedim Biotech. We are thus creating an excellent offering for the manufacturing of gene therapies and other advanced therapies, and are pleased to welcome 120 new employees,&...

Read More
news image

MEDTECH

WITH "PRODRUGS FOR CANCER TREATMENT" PATENT, GATC HEALTH ENTERS ONCOLOGY MEDICINE MARKET

GATC Health Corp | April 22, 2022

GATC Health, a biotech company that uses artificial intelligence and advanced multiomics to revolutionize drug discovery and disease prediction, announced that it filed a patent application for an innovative new prodrug designed to safely cross the blood-brain barrier (BBB) for cancer treatment. GATC Health's entry into the oncology drug discovery market is marked by this breakthrough, which was made possible by the company's innovative Multiomics Advanced TechnologyTM AI platform....

Read More
news image

RESEARCH

CHEMISTRY42, AN AI SYSTEM FROM INSILICO, HAS BEEN INCORPORATED INTO UCB'S DRUG DISCOVERY PROGRAMMES

Insilico Medicine | March 15, 2021

Insilico Medicine, an AI drug discovery company, reported that UCB will incorporate Insilico's Chemistry42™ into UCB's inward drug discovery pipeline. UCB's initial appropriation of Insilico Medicine's restrictive innovation will give UCB's researchers the capacity to plan novel hit compounds that fulfill various predefined boundaries quickly and smooth out lead enhancement. With the Chemistry42™ platform, UCB researchers will likewise lessen the endeavors and exp...

Read More